CIP2A and colorectal carcinoma: This study aimed to investigate the prognostic value of CIP2A (cancerous inhibitor of protein phosphatase 2A) and the NLR (neutrophil–lymphocyte ratio) in the serum of patients with CRC (colorectal cancer) after resection.